Stock listing
NYSE American:ARMP Armata Pharmaceuticals, Inc. Stock
Home listing (NYSE American) of Armata Pharmaceuticals, Inc.
Follow Armata Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · AMEX:ARMP
$3.03 USD -0.14 (-4.4%)
Close on Nov 20, 2026
- Day range
- $2.89 – $3.19 USDNov 20, 2026
- Volume
- 85,641 sharesNov 20, 2026
- Market cap
- $112.7M USDAt the close on Nov 20, 2026 · price × 37.19M shares outstanding
- 52-week range
- $2.40 – $14.98 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $839,482 USDMedian day 91,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:ARMP · Home | $3.03 USD | -0.14 (-4.4%) | 85,641 | $2.92 | $3.19 | $2.89 | $3.17 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:ARMP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.03 | -0.14 | -4.4% | $2.92 | $3.19 | $2.89 | 85,641 | |
| $3.17 | +0.51 | +19.2% | $2.59 | $3.17 | $2.57 | 89,167 | |
| $2.66 | -0.33 | -11.0% | $2.95 | $3.01 | $2.40 | 238,600 | |
| $2.99 | -0.88 | -22.7% | $3.84 | $4.13 | $2.98 | 159,500 | |
| $3.87 | +0.15 | +4.0% | $3.85 | $3.91 | $3.61 | 28,600 | |
| $3.72 | -0.17 | -4.4% | $3.85 | $3.90 | $3.54 | 105,100 | |
| $3.89 | +0.14 | +3.7% | $3.73 | $3.89 | $3.57 | 50,500 | |
| $3.75 | -0.05 | -1.3% | $3.54 | $3.77 | $3.43 | 64,000 | |
| $3.80 | +0.29 | +8.3% | $3.52 | $3.88 | $3.27 | 101,800 | |
| $3.51 | +0.51 | +17.0% | $3.00 | $3.51 | $3.00 | 69,300 | |
| $3.00 | -0.14 | -4.5% | $2.98 | $3.20 | $2.93 | 46,400 | |
| $3.14 | +0.05 | +1.6% | $3.12 | $3.32 | $3.07 | 64,200 | |
| $3.09 | +0.24 | +8.4% | $2.89 | $3.10 | $2.89 | 42,900 | |
| $2.85 | -0.43 | -13.1% | $3.28 | $3.31 | $2.80 | 85,900 | |
| $3.28 | +0.03 | +0.9% | $3.39 | $3.44 | $3.20 | 46,700 | |
| $3.25 | -0.04 | -1.2% | $3.28 | $3.40 | $3.15 | 102,900 | |
| $3.29 | -0.20 | -5.7% | $3.49 | $3.84 | $3.22 | 62,100 | |
| $3.49 | +0.04 | +1.2% | $3.40 | $3.73 | $3.40 | 104,300 | |
| $3.45 | -0.19 | -5.2% | $3.62 | $3.70 | $3.40 | 63,600 | |
| $3.64 | +0.19 | +5.5% | $3.44 | $3.80 | $3.44 | 115,600 | |
| $3.45 | +0.39 | +12.7% | $3.04 | $3.50 | $3.03 | 107,900 | |
| $3.06 | -0.14 | -4.4% | $3.21 | $3.21 | $2.94 | 93,600 | |
| $3.20 | +0.13 | +4.2% | $3.14 | $3.41 | $3.11 | 87,300 | |
| $3.07 | -0.30 | -8.9% | $3.33 | $3.41 | $3.07 | 88,300 | |
| $3.37 | +0.28 | +9.1% | $3.08 | $3.42 | $2.98 | 154,300 | |
| $3.09 | +0.31 | +11.2% | $2.86 | $3.16 | $2.83 | 115,700 | |
| $2.78 | -0.32 | -10.3% | $3.06 | $3.06 | $2.75 | 125,500 | |
| $3.10 | -0.53 | -14.6% | $3.68 | $3.68 | $3.01 | 223,200 | |
| $3.63 | 0.00 | 0.0% | $3.65 | $3.84 | $3.56 | 45,900 | |
| $3.63 | -0.23 | -6.0% | $3.90 | $3.95 | $3.62 | 100,600 | |
| $3.86 | +0.05 | +1.3% | $3.79 | $3.91 | $3.59 | 70,300 | |
| $3.81 | -0.04 | -1.0% | $3.83 | $4.07 | $3.72 | 103,600 | |
| $3.85 | +0.19 | +5.2% | $3.69 | $3.93 | $3.66 | 114,600 | |
| $3.66 | +0.14 | +4.0% | $3.54 | $3.68 | $3.51 | 56,600 | |
| $3.52 | +0.21 | +6.3% | $3.40 | $3.55 | $3.32 | 124,500 | |
| $3.31 | -0.36 | -9.8% | $3.67 | $3.78 | $3.28 | 76,400 | |
| $3.67 | +0.08 | +2.2% | $3.57 | $3.74 | $3.53 | 127,000 | |
| $3.59 | -0.19 | -5.0% | $3.74 | $3.74 | $3.52 | 91,800 | |
| $3.78 | +0.04 | +1.1% | $3.66 | $3.85 | $3.55 | 85,700 | |
| $3.74 | +0.12 | +3.3% | $3.60 | $3.81 | $3.56 | 100,800 | |
| $3.62 | -0.02 | -0.5% | $3.70 | $3.83 | $3.53 | 144,400 | |
| $3.64 | -0.56 | -13.3% | $4.20 | $4.30 | $3.60 | 286,900 | |
| $4.20 | -0.06 | -1.4% | $4.27 | $4.56 | $4.14 | 128,300 | |
| $4.26 | +0.08 | +1.9% | $4.24 | $4.36 | $4.10 | 82,900 | |
| $4.18 | +0.08 | +2.0% | $4.07 | $4.40 | $4.00 | 160,600 | |
| $4.10 | +0.03 | +0.7% | $4.32 | $4.32 | $4.09 | 253,300 | |
| $4.07 | -0.33 | -7.5% | $4.40 | $4.44 | $3.99 | 307,100 | |
| $4.40 | -1.15 | -20.7% | $5.24 | $5.35 | $4.23 | 646,200 | |
| $5.55 | +0.17 | +3.2% | $6.17 | $6.64 | $4.73 | 4,743,600 | |
| $5.38 | +0.15 | +2.9% | $5.30 | $5.55 | $5.26 | 43,600 | |
| $5.23 | -0.18 | -3.3% | $5.39 | $5.74 | $5.12 | 115,400 | |
| $5.41 | -0.41 | -7.0% | $5.76 | $5.79 | $5.40 | 17,900 | |
| $5.82 | -0.02 | -0.3% | $5.76 | $5.88 | $5.59 | 47,400 | |
| $5.84 | +0.32 | +5.8% | $5.49 | $5.87 | $5.48 | 48,000 | |
| $5.52 | -0.01 | -0.2% | $5.53 | $5.62 | $5.20 | 49,300 | |
| $5.53 | +0.25 | +4.7% | $5.36 | $5.62 | $5.27 | 70,100 | |
| $5.28 | -0.23 | -4.2% | $5.51 | $5.68 | $5.19 | 46,500 | |
| $5.51 | +0.14 | +2.6% | $5.35 | $5.52 | $5.18 | 51,500 | |
| $5.37 | -0.06 | -1.1% | $5.37 | $5.45 | $4.99 | 49,700 | |
| $5.43 | -0.02 | -0.4% | $5.42 | $5.47 | $4.73 | 270,500 | |
| $5.45 | -0.11 | -2.0% | $5.59 | $5.59 | $5.30 | 62,200 | |
| $5.56 | +0.39 | +7.5% | $5.23 | $5.70 | $5.23 | 94,290 | |
| $5.17 | +0.07 | +1.4% | $5.10 | $5.26 | $4.862 | 67,744 | |
| $5.10 | +0.68 | +15.4% | $4.42 | $5.10 | $4.42 | 111,500 | |
| $4.42 | -0.65 | -12.8% | $4.98 | $5.17 | $4.12 | 222,100 |
Splits
4 splits since 2006 · AMEX:ARMP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-14 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-50 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NYSE American:ARMP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
Latest deck · Nov 16, 2026
Investor Presentation (November 2026)
Investor deck · 52 slides
Latest news
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
Nov 12, 2026
Closed $3.87 (+4.0%) on Nov 13, 2026
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Sep 23, 2026
Closed $3.64 (-13.3%) on Sep 23, 2026
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Sep 21, 2026
Closed $4.26 (+1.9%) on Sep 21, 2026
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Sep 14, 2026
Closed $5.55 (+3.2%) on Sep 14, 2026
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026
Closed $5.23 (-3.3%) on Sep 10, 2026
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
Sep 3, 2026
Closed $5.52 (-0.2%) on Sep 3, 2026
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Aug 12, 2026
Closed $4.82 (+11.8%) on Aug 13, 2026
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
Jul 20, 2026
Closed $5.06 (+12.2%) on Jul 20, 2026
Armata Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 37 in all · newest Nov 12, 2026 · oldest 2024
- Decks
- 24 decks · latest Nov 16, 2026
Where Armata Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:ARMP · Home listing · This page | NYSE American | United States | USD |
| gettex:TG1N | gettex | Germany | EUR |
| Lang & Schwarz:A2PKLC | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2PKLC | LS Exchange | Germany | EUR |
| BOATS:ARMP | BOATS | United States | USD |
| Tradegate:TG1N | Tradegate | Germany | EUR |
| Dusseldorf:TG1N | Dusseldorf | Germany | EUR |
| Frankfurt:TG1N | Frankfurt | Germany | EUR |
| Munich:TG1N | Munich | Germany | EUR |
| Stuttgart:TG1N | Stuttgart | Germany | EUR |
Valuation
EV/sales 45.8× against a median of 9.9×: 5th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $346.0M USD
- P/E
- Loss
- EV/sales
- 45.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- −59.1%
- Operating margin
- −533.5%
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.97
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Armata Pharmaceuticals, Inc. · AMEX:ARMP | US$112.7M | US$346.0M | n/a | 45.8× | n/a | n/a | n/a | n/a | 0.97 |
| Curacle Co., Ltd. · KRX:365270 | US$117.6M | US$100.4M | n/a | 16.3× | n/a | 3.4× | −92.1% | 0.0× | n/a |
| PegBio Co., Ltd. Class H · HKEX:2565 | US$117.2M | US$55.97M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| enGene Therapeutics Inc. · NASDAQ:ENGN | US$116.6M | −US$149.7M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.82 |
| Sinew Pharma, Inc. · TPEX:6634 | US$114.4M | US$84.23M | n/a | 59,064× | n/a | 3.6× | n/a | 0.0× | n/a |
| Medigen Biotechnology Corporation · TPEX:3176 | US$111.8M | US$61.95M | n/a | 1.6× | n/a | 2.5× | −19.9% | 0.8× | n/a |
| Fate Therapeutics, Inc. · NASDAQ:FATE | US$111.7M | US$47.08M | n/a | 9.9× | n/a | 0.8× | n/a | 0.6× | 2.25 |
| OnKure Therapeutics, Inc. · NASDAQ:OKUR | US$109.4M | −US$53.16M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.17 |
| Spruce Biosciences, Inc. · NASDAQ:SPRB | US$109.2M | US$41.00M | n/a | n/a | n/a | 1.6× | n/a | 0.3× | 1.73 |
| NIBEC Co., Ltd. · KRX:138610 | US$108.7M | US$92.50M | n/a | 5.5× | 118× | 3.0× | −0.1% | 0.0× | n/a |
| Jyong Biotech Ltd. · NASDAQ:MENS | US$107.6M | US$125.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.74 |
| Median of the others | US$111.8M | US$58.96M | 9.9× | 118× | 2.5× | −19.9% | 0.0× | 1.74 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.46 · 1 analyst
- Revenue, year to Dec 2026
- 3.3M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Deborah Birx | Chief Executive Officer |
| David House | Chief Financial Officer |
| Peter Hubbard | Vice President of Operations |
| Bani Tchekanova | Head of Regulatory Strategy and Operations |
| Pierre Kyme | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Robin C. Kramer | Chair of Board of Directors |
| Daniel B. Gilmer | Director |
| Deborah Birx | Chief Executive Officer |
| Joseph M. Patti | Director |
| Jules Haimovitz | Director |
| Odysseas Kostas | Director |
| Sarah J. Schlesinger | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +4.0% |
| Q2 2026 | Aug 12, 2026 · After close | +11.8% |
| Q1 2026 | May 13, 2026 · After close | −7.0% |
| Q4 2025 | Mar 19, 2026 | −1.8% |
| Q3 2025 | Nov 12, 2025 · After close | −4.6% |
| Q2 2025 | Aug 12, 2025 · After close | +1.6% |
| Q1 2025 | May 14, 2025 · After close | +1.4% |
| Q4 2024 | Mar 19, 2025 · Before open | −2.9% |
| Q3 2024 | Nov 13, 2024 · After close | −1.5% |
| Q2 2024 | Aug 13, 2024 · After close | −10.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −3.5% |
| Q4 2023 | Mar 21, 2024 · After close | +1.4% |
| Q3 2023 | Nov 14, 2023 · After close | −19.8% |
| Q2 2023 | Aug 14, 2023 · Before open | −4.4% |
| Q1 2023 | May 11, 2023 · After close | −3.9% |
| Q4 2022 | Mar 16, 2023 · After close | +8.6% |
| Q3 2022 | Nov 9, 2022 · After close | −8.2% |
| Q2 2022 | Aug 11, 2022 · After close | −0.7% |
| Q1 2022 | May 12, 2022 · After close | +3.7% |
| Q4 2021 | Mar 17, 2022 · After close | +17.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 52 slides | Nov 16, 2026 |
| Investor Presentation (September 2026) | Investor deck | 52 slides | Sep 14, 2026 |
| IDWeek 2025 | Conference | 16 slides | Oct 22, 2025 |
| H.C. Wainwright 27th Annual Global Investment Conference (September 2025) | Conference | 29 slides | Sep 11, 2025 |
| Investor Presentation (May 2025) | Investor deck | 39 slides | May 19, 2025 |
| Investor Presentation (December 2024) | Investor deck | 34 slides | Dec 19, 2024 |
| Investor Presentation (August 2024) | Investor deck | 30 slides | Aug 26, 2024 |
| Investor Presentation (March 2023) | Investor deck | 31 slides | Mar 6, 2023 |
| Investor Presentation (January 2022) | Investor deck | 21 slides | Jan 5, 2022 |
| Investor Presentation (January 2021) | Investor deck | 23 slides | Jan 6, 2021 |
All 24 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.90M | 5.17M | 4.53M | 5.51M | 4.47M | 823.0K | 31.0K | 0 | 115.0K | 260.0K |
| Cost of revenue | 1.53M | 34.4M | 972.0K | 35.0M | 20.0M | 14.4M | 1.35M | 1.35M | 374.0K | 369.0K |
| Gross profit | 3.37M | -29.3M | 3.56M | -29.5M | -15.5M | -13.6M | -1.35M | -1.35M | -259.0K | -109.0K |
| Research and development | 23.7M | 34.4M | 33.8M | 35.0M | 20.0M | 14.4M | 9.82M | 8.37M | 2.88M | 5.68M |
| Selling, general and administrative | 12.4M | 13.2M | 11.6M | 7.44M | 8.28M | 7.97M | 9.27M | 5.70M | 7.59M | 8.41M |
| Operating income | -36.6M | -42.4M | -40.9M | -36.9M | -23.8M | -21.6M | -19.8M | -17.7M | -16.2M | -23.4M |
| Depreciation and amortization | 1.53M | 1.32M | 972.0K | 892.0K | 1.17M | 1.11M | 1.35M | 1.35M | 343.0K | 338.0K |
| EBITDA | -35.1M | -41.1M | -39.9M | -36.1M | -22.7M | -20.5M | -18.4M | -16.3M | -15.8M | -23.0M |
| Interest expense | 16.6M | 10.7M | 2.63M | 0 | 64.0K | 628.0K | 931.0K | 1.01M | 0 | 6.00K |
| Income before tax | -173.8M | -18.9M | -69.0M | -36.9K | -23.2M | -22.2M | -19.5M | -16.7M | -14.1M | -19.4M |
| Income tax | -29.0K | 64.0K | 634.0K | -454.0K | -328.0K | -1.30M | -556.0K | |||
| Net income | -173.8M | -18.9M | -69.0M | -36.9M | -23.2M | -22.2M | -19.5M | -16.7M | -12.8M | -18.8M |
| Earnings per share, basic | -4.80 | -0.52 | -1.91 | -1.08 | -0.96 | -1.35 | -2.49 | -3.59 | -2.01 | -24.67 |
| Earnings per share, diluted | -4.80 | -0.89 | -1.91 | -1.08 | -0.96 | -1.35 | -2.55 | -3.59 | -2.18 | -24.67 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.69M | 9.29M | 13.5M | 14.9M | 10.3M | 9.65M | 6.03M | 9.66M | 5.13M | 5.13M |
| Short-term investments | 9.65M | |||||||||
| Receivables | 472.0K | 744.0K | 3.36M | 8.53M | 2.99M | 561.0K | 12.0K | |||
| Inventory | -2.99M | -561.0K | -619.0K | |||||||
| Current assets | 10.7M | 11.3M | 19.2M | 27.0M | 15.0M | 10.8M | 6.66M | 10.4M | 5.38M | 6.31M |
| Property, plant and equipment | 12.2M | 13.2M | 12.6M | 3.62M | 2.22M | 2.05M | 2.19M | 3.25M | 816.0K | 1.07M |
| Goodwill | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 0 | ||
| Total assets | 76.9M | 86.4M | 98.4M | 95.8M | 69.8M | 39.5M | 25.5M | 14.5M | 11.1M | 18.2M |
| Accounts payable | 921.0K | 766.0K | 1.58M | 1.68M | 1.14M | 956.0K | 547.0K | 415.0K | 578.0K | 1.06M |
| Current liabilities | 8.95M | 48.2M | 16.5M | 24.9M | 4.81M | 6.71M | 4.88M | 2.03M | 1.97M | 3.54M |
| Long-term debt | 256.9M | 55.4M | 82.3M | |||||||
| Total debt | 288.0M | 126.5M | 120.4M | 48.8M | 38.0M | 13.2M | 2.86M | 803.0K | ||
| Total liabilities | 295.5M | 134.5M | 130.4M | 59.8M | 44.4M | 20.7M | 10.9M | 6.85M | 3.41M | 8.43M |
| Shareholders' equity | -218.6M | -48.0M | -32.1M | 36.1M | 25.4M | 18.9M | 14.6M | 7.69M | 24.3M | 9.72M |
| Shares outstanding | 36.4M | 36.2M | 36.1M | 36.1M | 27.1M | 18.7M | 9.92M | 5.07M | 9.50M | 1.65M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -25.8M | -37.6M | -47.4M | -32.5M | -23.6M | -18.3M | -15.6M | -10.6M | -9.19M | -10.6M |
| Capital spending | -542.0K | -1.88M | -8.14M | -2.21M | -1.30M | -824.0K | -224.0K | -875.0K | -58.0K | -279.0K |
| Free cash flow | -26.3M | -39.4M | -55.6M | -34.7M | -24.9M | -19.1M | -15.8M | -11.5M | -9.25M | -10.9M |
| Cash from investing | -542.0K | -1.88M | -8.13M | -2.21M | -1.30M | -824.0K | 2.88M | 8.81M | -58.0K | -279.0K |
| Cash from financing | 25.6M | 35.0M | 54.0M | 44.0M | 25.5M | 23.2M | 8.97M | 12.5M | 8.67M | 7.23M |
| Dividends paid | 0 | -80.0K | ||||||||
| Share buybacks | -43.0K | 44.5M | 26.9M | 23.1M | 9.97M | 12.5M | 9.49M | -173.0K | ||
| Change in cash | -693.0K | -4.47M | -1.57M | 9.32M | 639.0K | 4.12M | -3.73M | -1.81M | -579.0K | -3.66M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 8-K · Current report | Sep 23, 2026 | Current report | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| 8-K · Current report | Jul 20, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Jul 10, 2026 | Offer document | SEC |
| 8-K/A · Current report, amended | Jun 24, 2026 | Management or board change | SEC |
| 8-K · Current report | Jun 23, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 8-K · Current report | May 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 28, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 27, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 27, 2026 | Management or board change | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| 8-K · Current report | Mar 19, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 23, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 26, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 13, 2026 | Current report | SEC |
| 8-K · Current report | Dec 1, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 1, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 8-K · Current report | Sep 10, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 25, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 15, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2025 | Offer document | SEC |
| S-3 · Registration statement | Aug 13, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 19, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Apr 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 12, 2025 | Material contract | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2024 | Current report | SEC |
| 8-K · Current report | Dec 4, 2024 | Management or board change | SEC |
| 8-K · Current report | Nov 15, 2024 | Material contract | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| 8-K · Current report | Oct 3, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 26, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 15, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Jul 25, 2024 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jun 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 22, 2024 | Current report | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 4, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jan 23, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 15, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| UPLOAD · Letter from the SEC | Nov 13, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 7, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 26, 2023 | Other filings | SEC |
| 3 · Initial statement of ownership | Sep 22, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 20, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Aug 3, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Aug 3, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 3, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 24, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jul 19, 2023 | Management or board change | SEC |
| 3 · Initial statement of ownership | Jul 19, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 11, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jul 11, 2023 | Material contract | SEC |
| 8-K · Current report | Jun 27, 2023 | Results | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 3 · Initial statement of ownership | May 8, 2023 | Insider trade | SEC |
| 8-K · Current report | May 5, 2023 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Apr 7, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Apr 6, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 5, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | Mar 28, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 16, 2023 | Results | SEC |
| 10-K · Annual report | Mar 16, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Feb 17, 2023 | Other filings | SEC |
| S-3 · Registration statement | Feb 13, 2023 | Offer document | SEC |
| 3 · Initial statement of ownership | Feb 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 10, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 10, 2023 | Material contract | SEC |
| 8-K · Current report | Dec 19, 2022 | Management or board change | SEC |
| 8-K · Current report | Nov 18, 2022 | Meeting outcome | SEC |
| 8-K · Current report | Nov 9, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2022 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Oct 17, 2022 | Meeting notice | SEC |
| 8-K · Current report | Sep 20, 2022 | Results | SEC |
| 8-K · Current report | Aug 11, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Jun 1, 2022 | Other filings | SEC |
| 424B3 · Prospectus | May 31, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 26, 2022 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 23, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 19, 2022 | Other filings | SEC |
| S-3 · Registration statement | May 13, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Apr 15, 2022 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 7, 2022 | Other filings | SEC |
| 424B3 · Prospectus | Apr 6, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 5, 2022 | Other filings | SEC |
| 4 · Change in ownership | Apr 1, 2022 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 1, 2022 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2022 | Other filings | SEC |
| 8-K · Current report | Mar 31, 2022 | Meeting outcome | SEC |
| S-3 · Registration statement | Mar 29, 2022 | Offer document | SEC |
| 8-K · Current report | Mar 28, 2022 | Management or board change | SEC |
| 10-K · Annual report | Mar 17, 2022 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 9, 2022 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Feb 24, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 11, 2022 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 11, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2022 | Material contract | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Armata Pharmaceuticals, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 37,192,632
- Fully diluted
- 37,192,632
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 37,192,632 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 37,192,632 |
| Nov 6, 2026 | 37,192,632 |
| Aug 6, 2026 | 37,181,979 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Vijay B Samant Other companies: Brickell Biotech Inc (Director · Feb 14, 2020 – May 17, 2022 · Past); Raptor Pharmaceutical Corp (Director · Apr 11, 2011 – Apr 7, 2014 · Past); Vical Incorporated (President & CEO, Director · Apr 6, 2007 – Jun 18, 2018 · Past) | Director · Nov 5, 2015 – Sep 7, 2017 · Past |
| Kostas D Odysseas Other companies: Amarin Corporation plc (Director · Since at least Apr 18, 2024); Innoviva, Inc. (Director · Jun 17, 2024 – Jun 17, 2024 · Past) | Director · Since at least Dec 21, 2023 |
| Wendy S Johnson Other companies: OnKure Therapeutics, Inc. (Chief Development Officer · Apr 8, 2021 – Jul 14, 2021 · Past); Exagen Inc. (Director · Oct 1, 2020 – Jun 9, 2023 · Past) | Director · Sep 8, 2015 – Sep 7, 2017 · Past |
| Deborah Birx Other companies: Innoviva, Inc. (Director · Mar 9, 2021 – May 22, 2023 · Past) | Chief Executive Officer · Since at least Jul 10, 2023 |
| Erin Butler Other companies: ImageneBio, Inc. (Principal Accounting Officer · Since at least Jul 25, 2025) | Vice President,Finance & Admin · Jul 1, 2022 – Jul 1, 2022 · Past |
| Jules Haimovitz Other companies: Innoviva, Inc. (Director · Since at least Feb 12, 2018) | Director · Since at least Apr 1, 2021 |
| Odysseas Kostas Other companies: Amarin Corporation plc (Non-Executive Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
| Richard Bear Other companies: CRH Medical Corporation (Chief Financial Officer · Jan 1, 2019 – Apr 22, 2021 · Past) | Director · May 9, 2019 – May 22, 2019 · Past |
| Robin Kramer Other companies: Biogen Inc. (Chief Financial Officer · Since at least Dec 3, 2020) | Chair of Board of Directors · Since at least Dec 8, 2020 |
| Sarah J. Schlesinger Other companies: Innoviva, Inc. (Board Member · Since at least May 6, 2026) | Director · Since at least Nov 5, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Steve Martin Other companies: Ensysce Biosciences, Inc. (Director · Since at least Jun 30, 2021) | Chief Financial Officer · Dec 9, 2016 – Mar 25, 2021 · Past |
| Todd Patrick Other companies: CRH Medical Corporation (Director · Apr 22, 2021 – Apr 22, 2021 · Past) | Director · Dec 8, 2020 – Apr 13, 2022 · Past |
| Bani Tchekanova | Head of Regulatory Strategy and Operations · Since at least Nov 5, 2026 |
| BG Susan Robinson | President and CEO, Director · Nov 6, 2008 – Apr 16, 2010 · Past |
| Daniel B. Gilmer | Director · Since at least Apr 24, 2026 |
| David House | Chief Financial Officer · Since at least Aug 12, 2026 |
| Duane Alfred Morris | VP of Operations · Apr 13, 2022 – Apr 13, 2022 · Past |
| Joseph M. Patti | Director · Since at least May 9, 2019 |
| Peter Hubbard | Vice President of Operations · Since at least Nov 4, 2026 |
| Pierre Kyme | Chief Business Officer · Since at least Jun 19, 2024 |
| Richard Bastiani | Director · Dec 8, 2020 – Dec 8, 2020 · Past |
Log in to ask 6ix AI your own questions about Armata Pharmaceuticals, Inc.